Comparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Fresh Tracks Therapeutics, Inc. ?
Unrated Stock - No Analysis Available
How much should you buy?
- Overall Portfolio exposure to Fresh Tracks Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals: Major should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals: Major)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
No Data Found
Quality key factors
Factor
Value
Sales Growth (5y)
37.66%
EBIT Growth (5y)
10.70%
EBIT to Interest (avg)
-21.63
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.09
Sales to Capital Employed (avg)
0.45
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
11.42%
ROCE (avg)
0
ROE (avg)
0
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.56
EV to EBIT
0.83
EV to EBITDA
0.84
EV to Capital Employed
5.28
EV to Sales
-0.66
PEG Ratio
NA
Dividend Yield
4939.99%
ROCE (Latest)
636.00%
ROE (Latest)
-59.33%
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
Mildly Bullish
Technical Movement
Not enough Data to analyse Financial Trend
Not enough Data to analyse Financial Trend
Here's what is working for Fresh Tracks Therapeutics, Inc.
Net Sales
At USD 7.94 MM has Grown at 213.25%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD -4.35 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Higher at USD 7.94 MM
than preceding 12 month period ended Dec 2023MOJO Watch
In the half year the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Pre-Tax Profit
At USD -1.24 MM has Grown at 44.87%
over average net sales of the previous four periods of USD -2.25 MMMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
At USD -1.24 MM has Grown at 46.06%
over average net sales of the previous four periods of USD -2.29 MMMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Debtors Turnover Ratio
Highest at 29.17%
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Here's what is not working for Fresh Tracks Therapeutics, Inc.
Raw Material Cost
Grown by 101.02% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales






